falsefalse

Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial Cancer - Episode 10

Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

,

Floor Backes, MD, closes the discussion by explaining that endometrial cancer care is rapidly evolving and complicated, requiring calling on colleagues for guidance, getting molecular profiling, and encouraging trial participation.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Recent Advances in Endometrial Cancer
    EP. 2: Key Takeaways From the 2023 Society of Gynecologic Oncology (SGO) Annual Meeting
    EP. 3: Current Data on Single-Agent Immunotherapy in Advanced Endometrial Cancer
    EP. 4: Dostarlimab Plus Chemotherapy for the Treatment of Advanced Endometrial Cancer: Data from the RUBY Trial
    EP. 5: Data From the AtTEnd: Study: Atezolizumab Plus Carboplatin and Paclitaxel for Treatment of Advanced Endometrial Cancer
    EP. 6: The Impact of Real-World Evidence on the Treatment of Patients With Advanced Endometrial Cancer
    EP. 7: Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
    EP. 8: The TROPiCS-03 Study: Sacituzumab Govitecan in Patients With Advanced Endometrial Cancer
    EP. 9: Unmet Needs in the Management of Patients With Advanced Endometrial Cancer
    Now Viewing
    EP. 10: Clinical Pearls for Community Oncologists Treating Patients With Advanced Endometrial Cancer

    Related Content:

    Post-Conference Perspectives Year in Review: 2023 Developments in Advanced or Recurrent Endometrial CancerOncLive News Network®Gynecologic Oncology
    Novel Treatment Approaches Under Investigation in ROS1+ NSCLC
    Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC
    Pooled Data for Taletrectinib in ROS1+ NSCLC
    x